Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
akcea therapeutics
boston blog main
boston top stories
inotersen
life sciences
national blog main
national top stories
new york blog main
new york top stories
3
×
onpattro
patisiran
3
×
pfizer
san diego blog main
san diego top stories
tafamidis
alnylam pharmaceuticals
boston
clinical trials
drugs
fda
hereditary transthyretin amyloidosis
andrew fire
anylam pharmaceuticals
cardiomyopathy
craig mello
european medicines agency
harvard pilgrim health care
institute for clinical and economic review
john maraganore
neuropathy
new york
nobel prize
rna interference
san francisco blog main
san francisco top stories
tegsedi
transthyretin amyloidosis
vyndaqel
What
alnylam
3
×
drug
3
×
fda
approved
medicine
rnai
afternoon
ago
akcea
alnylam’s
amyloidosis
approves
attr
available
battle
cells
debilitating
disease
ema
employ
europe
follows
gene
genetic
gets
harmful
history
hits
interference
landmark
make
making
medicines
method
mute
ok
oks
onpattro
patients
patisiran
Language
Current search:
alnylam
×
drug
×
" new york top stories "
×
patisiran
×
@xconomy.com
5 years ago
FDA OKs Pfizer Rare Disease Drug, Sets Up Battle With Alnylam, Akcea
@xconomy.com
6 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
6 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug